NEW YORK – San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer's cMET inhibitor crizotinib (Xalkori).
Ideaya, which develops precision oncology drugs for patients selected using molecular diagnostics, is evaluating the IDE196-crizotinib combination in metastatic uveal melanoma patients following results from preclinical research demonstrating synergistic activity between the two agents. Mick O'Quigley, Ideaya's VP and head of development operations, said in a statement that the company decided to advance the combination to clinical trials based on translational research that included evaluation of cMET expression in samples from metastatic uveal melanoma patients.
The firm has plans to share the results of that preclinical research in the first half of this year.
The latest uveal melanoma clinical trial is part of Ideaya's ongoing collaboration with Pfizer. The companies announced that their existing collaboration had been expanded to incorporate the IDE196-crizotinib combination in September 2020.
Ideaya is also evaluating IDE196 both alone and in combination with binimetinib (Pfizer/ Array Biopharma's Mektovi) in a basket trial for patients with solid tumors, including those harboring GNAQ or GNA11 mutations or PRKC fusions.